Short answer
Perspective Therapeutics, Inc. (CATX) filed an 8-K current report with the SEC on August 10, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Q2 2026 results and recent business highlights announced for quarter ended June 30, 2026.
Perspective Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results and recent business highlights announced for quarter ended June 30, 2026
- Full financial figures and operating updates contained in furnished Exhibit 99.1 press release
- Results announcement provides investors an update on Perspective Therapeutics’ clinical and corporate progress
Item 8.01 · Other Events
- August 10, 2026 8-K includes a company press release as Exhibit 99.1
- Corporate presentation included as Exhibit 99.2, potentially containing material investor updates
- Filing signed by CFO Joel Sendek on August 10, 2026
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and short-term investments $237M at June 30, 2026, funding planned milestones and operations into late 2027
- VMT-α-NET Phase 3 site activation targeted around year-end 2026, pending regulatory alignment and protocol finalization
- VMT-α-NET data presentation scheduled at ESMO October 23, offering a near-term clinical catalyst
- Second-quarter R&D expense rose to $21.5M from $16.6M, reflecting continued pipeline and manufacturing investment
- Net loss widened to $26.8M from $21.5M, while loss per share improved to $0.22 from $0.29 on higher share count
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Perspective Therapeutics, Inc. 8-K filings
Get the next CATX 8-K as it lands
Follow CATX for push alerts, or ask the research agent what this filing means.